You are here
Professor Florian Lordick
University Hospital Leipzig, Leipzig, Germany
Florian Lordick, MD, PhD, is Professor of Oncology and Director of the University Cancer Centre Leipzig (UCCL) at the University Hospital Leipzig in Germany. Professor Lordick completed his medical training at the universities of Regensburg and Munich in Germany, and Lausanne in Switzerland. He gained board certifications in internal medicine, haematology, and medical oncology, and in 2002 he was appointed consultant physician at the Technical University of Munich. In July 2007 he was nominated Assistant Professor and Head of the Outpatient Department at the National Centre for Tumour Diseases, University of Heidelberg, Germany; in 2009 he was appointed Head of Haematology and Oncology at the Klinikum Braunschweig in Braunschweig, Germany, and Associate Professor at Hannover Medical School in Hannover, Germany. He took up his current posts as Full Professor at the University of Leipzig and Director of the UCCL in 2012.
Professor Lordick is a member of the Board of Directors of the German Cancer Society and Secretary of the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group. In 2015 he was elected as incoming President of the International Gastric Cancer Association (IGCA) and as Congress Chair of the 2019 International Gastric Cancer Congress, to be held in Prague.
Professor Lordick’s scientific focus is on clinical and translational research in gastrointestinal cancer, the optimization of multimodal care, new drug development, molecular imaging, and response prediction. He has authored or co-authored more than 200 articles on gastrointestinal cancer; he is co-editor of a number of important international oncology journals and a reviewer for international and national research and funding societies.
Articles commented by Professor Lordick
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka SAnn Oncol 2016 Jan 7. pii: mdv625. [Epub ahead of print]
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, et al.Br J Cancer 2016 Feb 16;114(4):381-7
Kang BW, Seo AN, Yoon S, Bae HI, Jeon SW, Kwon OK, etal.Ann Oncol. 2016 Mar;27(3):494-501
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al.Lancet Oncol. 2016 Mar;17(3):309-18
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss-Patience, Florian Bassermann, Ulrike Helbig, Florian Weißinger, Elisabeth Schnoy, Klaus Becker, Gertraud Stocker, Josef Rüschoff, Andreas Eisenmenger, Irini Karapanagiotou-Schenkel, Florian Lordick
European Journal of Cancer, Volume 51, Issue 5, March 2015, Pages 569 - 576
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
Min-Hee Ryu, Changhoon Yoo, Jong Gwang Kim, Baek-Yeol Ryoo, Young Soo Park, Sook Ryun Park, Hye-Suk Han, Ik Joo Chung, Eun-Kee Song, Kyung Hee Lee, Seok Yun Kang, Yoon-Koo Kang
European Journal of Cancer, Volume 51, Issue 4, March 2015, Pages 482 - 488
Validating the prognostic and discriminating value of the TNM-classification for gastric cancer – A critical appraisal
C. Röcken, H.-M. Behrens
European Journal of Cancer, Volume 51, Issue 5, March 2015, Pages 577 - 586
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
Katsuhiko Higuchi, Satoshi Tanabe, Ken Shimada, Hisashi Hosaka, Eisaku Sasaki, Norisuke Nakayama, Yuiti Takeda, Toshikazu Moriwaki, Kenji Amagai, Takashi Sekikawa, Toshikazu Sakuyama, Tatsuo Kanda, Tohru Sasaki, Mizutomo Azuma, Fumiaki Takahashi, Masahiro Takeuchi, Wasaburo Koizumi, The Tokyo Cooperative Oncology Group, Tokyo, Japan.
European Journal of Cancer, Volume 50, Issue 8, May 2014, Pages 1437 - 1445
N. Abbassi-Ghadi, S. Kumar, J. Huang, R. Goldin, Z. Takats, G.B. Hanna
European Journal of Cancer, Volume 49, Issue 17, November 2013, Pages 3625 - 3637
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
European Journal of Cancer, Volume 49, Issue 7, May 2013, Pages 1565 - 1577